We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ZyGEM to Commercialize DNA Detection and Testing Platform

By LabMedica International staff writers
Posted on 07 Jun 2010
ZyGEM Corp. More...
Ltd. (Hamilton, New Zealand; and Solana Beach, CA, USA) has acquired MicroLab Diagnostics Inc., a private company developing microfluidic devices for rapid DNA testing. ZyGEM will market products integrating its DNA extraction, reagents, and detection assays with microfluidic chip technology developed by MicroLab, which will operate as a business unit of the new company.

MicroLab's miniaturization of the entire DNA testing process within a single closed system significantly reduces the amount of sample and reagents that are needed, while virtually eliminating the chances for handling error or contamination. The integrated new products will dramatically decrease the time, complexity, and cost of conducting DNA testing and have transformational potential in a broad range of applications.

The ZyGEM/MicroLab system is compact, easy-to-use, and cost-effective, making it suitable for use both in the laboratory and out in the field. It can perform multiplexed analyses, and it can also be configured for specific applications. Portable handheld versions are in development.

A prototype of the new system produced accurate DNA results in less than an hour, comparable to results obtained with current technology requiring three separate instruments and 5 to 10 hours. The new technology has the potential for applications where accuracy, speed, and ease-of-use are critical, including, point-of-care diagnostics, forensics, biodefense, and food pathogen testing.

ZyGEM intends to continue to expand sales of its proprietary assays and kits that use a thermophilic enzyme to extract DNA or RNA from a wide range of sample types using a single, closed-tube system.

Under the terms of the agreement, the new company will be called ZyGEM and will be headquartered in Charlottesville, Virginia (USA).

Dr. James Landers, cofounder of MicroLab Diagnostics and CSO of the new company, noted, "ZyGEM brings us DNA extraction and detection technology that is an ideal fit with our microchips, enabling us to achieve a seamless sample-to-answer solution with broad market applicability. It also brings us commercial expertise and a global network of distributors and partners.

Related Links:

ZyGEM Corp. Ltd.
MicroLab Diagnostics Inc.



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.